全文获取类型
收费全文 | 215篇 |
免费 | 7篇 |
专业分类
儿科学 | 36篇 |
妇产科学 | 2篇 |
基础医学 | 15篇 |
临床医学 | 14篇 |
内科学 | 62篇 |
皮肤病学 | 2篇 |
神经病学 | 20篇 |
外科学 | 38篇 |
综合类 | 1篇 |
预防医学 | 2篇 |
药学 | 6篇 |
肿瘤学 | 24篇 |
出版年
2017年 | 2篇 |
2016年 | 3篇 |
2015年 | 4篇 |
2014年 | 3篇 |
2013年 | 6篇 |
2012年 | 1篇 |
2010年 | 6篇 |
2009年 | 5篇 |
2007年 | 4篇 |
2006年 | 15篇 |
2005年 | 10篇 |
2004年 | 8篇 |
2003年 | 5篇 |
2002年 | 3篇 |
2001年 | 4篇 |
2000年 | 2篇 |
1999年 | 3篇 |
1998年 | 18篇 |
1997年 | 12篇 |
1996年 | 20篇 |
1995年 | 18篇 |
1994年 | 12篇 |
1993年 | 10篇 |
1991年 | 4篇 |
1989年 | 3篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 11篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 2篇 |
1982年 | 5篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1979年 | 3篇 |
1978年 | 2篇 |
1976年 | 1篇 |
1975年 | 2篇 |
1970年 | 1篇 |
1968年 | 1篇 |
1952年 | 1篇 |
排序方式: 共有222条查询结果,搜索用时 625 毫秒
1.
SUGA JUNJI; SAIJO NAGAHIRO; SHINKAI TETSU; EGUCHI KENJI; SASAKI YASUTSUNA; SAKURAI MASANORI; SANO TETSURO; TAMURA TOMOHIDE; HOSHI AKIO 《Japanese journal of clinical oncology》1986,16(2):147-151
A phase II study of mitoxantrone was performed in 24 patientswith non-small cell lung cancer (NSCLC). Mitoxantrone was administeredby intravenous drip infusion of 12 mg/m2 every three weeks.There were no responders among the 21 evaluable patients includingfive patients without prior therapy. The major hematologicaltoxic effect was leukocytopenia. Thrombocytopenia and decreasein hemoglobin were slight. A change in the electrocardiogramwas observed in one patient and one patient experienced cardiogenicshock. Mitoxantrone is not acceptable for the treatment of NSCLC becauseof its low antitumor activity, and careful observation is neededfor administration of this agent to patients with pre-existingrisk factors, such as prior anthracycline exposure, mediastinalradiation or underlying cardiovascular disease. 相似文献
2.
MASATO FUKUDA MD AKINOBU HATA MD SHIN-ICHI NIWA MD KEN-ICHI HIRAMATSU MD MASAFUMI YOKOKOJI MD SEIKI HAYASHIDA AM KENJI ITOH DENG KAZUYUKI NAKAGOME MD AKIRA IWANAMI MD 《Psychiatry and clinical neurosciences》1996,50(2):85-88
Abstract A female patient exhibiting functional hearing loss in her left ear demonstrated reduced amplitude of P3 component in event-related potentials (ERP) to left monaural stimulation, with preserved N1 and N2 components to stimulation of either ear. This result suggested that stimuli in the affected ear were conducted successfully up to the auditory cortex but that further processing in higher brain regions was 'repressed'. Event-related potential examination for such hysterical disorders could be useful in clarifying their brain mechanism and offer a useful diagnostic clue to its nature. 相似文献
3.
4.
TOMOHITO GOHDA MITSUO TANIMOTO KAORI WATANABE-YAMADA MASAKAZU MATSUMOTO SHIGERU KANEKO SHINJI HAGIWARA KENJI SHIINA TOSHIHIDE SHIKE KAZUHIKO FUNABIKI YASUHIKO TOMINO 《Nephrology (Carlton, Vic.)》2005,10(S2):S22-S25
SUMMARY: Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD) in Japan, Western Europe, and the United States. Mega studies such as Diabetes Control and Complication Trial (DCCT), Epidemiology of Diabetes Interventions and Complications (EDIC), and the United Kingdom Prospective Diabetes Study (UKPDS) clarified that poor glycemic and blood pressure control are undoubtedly involved in the development of nephropathy. However, these factors are not sufficient to predict which diabetic patients will develop renal disease, because not all patients with poor glycemic and blood pressure control develop renal disease. Since ethnic variations and familial clustering of diabetic nephropathy have been observed, genetic factors might contribute to susceptibility to this disease. Several methods such as (genome wide) association studies, sib-pair analysis, and quantitative trait loci (QTLs) analysis are available to examine polygenic diseases. However, no mutations that could explain the majority of nephropathy cases have been identified so far. The development of most diabetic nephropathy might be explained by the polygenic effect (i.e. many minor gene-gene interactions might be very important in the development of nephropathy). Identification of candidate genes of nephropathy enables targeting of therapy in patients at risk and development of novel therapeutic agents. 相似文献
5.
6.
TENGAN ISAMU; SUEMASU KEIICHI; EGUCHI KENJI; KODAMA TETSURO; SHIMOSATO YUKIO; KAJITA MASAFUMI; TSUCHIYA RYOSUKE 《Japanese journal of clinical oncology》1981,11(2):343-352
Forty-eight cases of surgically resected benign tumors and tumor-likelesions of the lung were analyzed, with the following results:1) Hamartoma and sclerosing hemangioma have well defined borders,compressing bronchi and blood vessels, and are loosely boundto the surrounding lung parenchyma. 2) Hamartomas, in 90% ofthe cases, showed "nodularity" on film tomograms. Histologically,nodularity at the edge was produced by lobules of cartilage.3) Fifty-three percent of the patients with sclerosing hemangiomawere middle-aged females and asymptomatic. Only two patientscomplained of hemosputum. Routine roentgenograms showed a roundshadow with homogeneous density. Cut surfaces were solid withvarious degrees of hasemorrhage. 4) Roentgenograms of benignmesothelioma showed large tumors more than 4 cm in diameter,in which extrapleural signs could be observed. 5) "Calcification"was seen on the roentgenograms of seven out of 27 hamartomasand one out of 15 sclerosing hemangiomas. Pleural retractioncould not be seen in our series. Xerotomography was superiorto film tomography in showing calcification. 6) One of the sclerosinghemangiomas was double, and the other 47 benign tumors and tumor-likelesions were solitary; the lesions were peripheral in 45 casesand central in three. All of the patients were free of localrecurrence and distant metastasis. 相似文献
7.
YUKIHIKO KAWASAKI MITSUAKI HOSOYA SEIJI YASUMURA TETSUYA OHIRA HIROAKI SATOH HITOSHI SUZUKI AKIRA SAKAI AKIRA OHTSURU ATSUSHI TAKAHASHI KOTARO OZASA GEN KOBASHI KENJI KAMIYA SHUNICHI YAMASHITA MASAFUMI ABE THE FUKUSHIMA HEALTH MANAGEMENT SURVEY GROUP 《Fukushima journal of medical science》2015,61(2):101-110
8.
SHU TAKABATAKE M.D. KENSHI HAYASHI M.D. CHIAKI NAKANISHI M.D. HIROYUKI HAO M.D. KENJI SAKATA M.D. MASA‐AKI KAWASHIRI M.D. TAKEHISA MATSUDA Ph.D. MASAKAZU YAMAGISHI M.D. 《Journal of interventional cardiology》2014,27(1):63-72
Objectives
We evaluated the in vivo performance of a newly devised vascular endothelial growth factor (VEGF)‐bound stent in a porcine coronary model.Background
An anti‐CD34 antibody‐bound stent, which captures endothelial progenitor cells (EPCs) to accelerate tissue formation, did not reduce intimal hyperplasia. By targeting the VEGF receptor, which is expressed on endothelial‐lineage cells, we developed VEGF‐bound stents that may enable selective capture of EPCs followed by rapid endothelialization.Methods
Metallic stents were first coated with poly‐(ethylene‐co‐vinyl alcohol), and then chemically bound with either VEGF or anti‐CD34 antibody. These stents were placed in porcine coronary arteries for up to 14 days. Stent surface was evaluated by immunohistochemistry and by scanning electron microscope (SEM).Results
After 2‐day stenting with VEGF‐bound stents, small populations of KDR (VEGF receptor‐2)‐positive cells adhered to the stent struts. After 7‐ and 14‐day stenting, struts were fully covered with newly regenerated tissue. SEM images showed that the uniform tissue formed on struts was morphologically similar to native endothelium and was continuously connected with adjacent native endothelium. On the other hand, for the anti‐CD34 antibody‐bound stents, stent struts were rapidly covered by newly generated tissue that consisted of multicellular aggregates.Conclusions
Compared with anti‐CD34 antibody‐bound stents, VEGF‐bound stents provide highly selective capture of EPCs, followed by rapid formation of intact endothelium tissue at an early period of stenting. These results suggest that VEGF‐bound stents could represent a promising therapeutic option for cardiovascular stenting, although further long‐term follow‐up experiment with double‐blinded fashion is needed prior to clinical application. (J Interven Cardiol 2014;27:63–72)9.
TAISHI KUWAHARA M.D. ATSUSHI TAKAHASHI M.D. YOSHIHIDE TAKAHASHI M.D. ATUSHI KOBORI M.D. SHINSUKE MIYAZAKI M.D. ASUMI TAKEI M.D. TADASHI FUJINO M.D. KENJI OKUBO M.D. KATSUMASA TAKAGI M.D. AKIRA FUJII M.D. MASATERU TAKIGAWA M.D. YUJI WATARI M.D. HIROYUKI HIKITA M.D. AKIRA SATO M.D. KAZUTAKA AONUMA M.D. 《Journal of cardiovascular electrophysiology》2013,24(5):510-515
10.
To observe the secular trend of a proportion of Kawasaki disease patients with cardiac sequelae in Japan, we analyzed patients with Kawasaki disease reported to nationwide surveys of the disease during 10.5 years from July 1982 to December 1992. Of 69 382 patients reported to the surveys, 10 596 (15.3%) were reported to have cardiac sequelae such as dilatation or stenosis of coronary arteries, myocardial infarction or valvar lesions, 1 month or more after onset. The percentage of cardiac sequelae was particularly high in males, infants younger than 1 year and children older than 5 years of age. The overall prevalence declined steadily over the observed period. However, the percentage for children older than 5 years of age did not decrease, whether treated with intravenous gamma globulin or untreated. As a consequence of the increased number of patients treated with intravenous gamma globulin, the proportion of Kawasaki disease patients with cardiac sequelae decreased annually. However, the proportion of children older than 5 years of age did not decrease. 相似文献